血清miR-10b在乳腺浸润性导管癌中的表达及临床意义  

Expression of serum miR-10b in invasive ductal breast cancer and its diagnostic value

作　　者：李龙均 付明刚[1] 迪丽米娜·伊拉木[1] 马方婧[1] 耿贝贝 郭丽英[1] LI Longjun;FU Minggang;Dilimina YILAMU;MA Fangjing;GENG Beibei;GUO Liying(Department of Breast Surgery , the First Affiliated Hospital of Xinjiang Medical University , Urumqi 830011, China)

机构地区：[1]新疆医科大学第一附属医院乳腺外科

出　　处：《中华实用诊断与治疗杂志》2019年第8期750-752,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：新疆重大疾病医学重点实验室专项项目(SKLI-XJMDR-ZX-2014-1)

摘　　要：目的探讨乳腺浸润性导管癌患者血清miR-10b表达情况及其与临床病理特征的关系。方法乳腺浸润性导管癌患者29例为乳腺癌组,成年女性体检健康者48例为对照组;采用实时荧光定量PCR法检测2组血清miR-10b相对表达量;绘制ROC曲线,评估血清miR-10b水平对乳腺浸润性导管癌的诊断价值,分析其与临床病理特征的关系。结果乳腺癌组血清miR-10b相对表达量(2.140±1.769)高于对照组(1.408±1.328)(P<0.05);当血清miR-10b最佳截断值为0.334时,诊断乳腺浸润性导管癌的AUC为0.646(95%CI:0.523~0.769),灵敏度为89.70%,特异度为41.70%;乳腺癌组术前有淋巴结转移患者血清miR-10b相对表达量(3.449±1.855)高于无淋巴结转移者(1.077±0.630)(P<0.05),不同年龄、月经状态、肿瘤直径及雌激素受体、孕激素受体、人表皮生长因子受体-2阳性或阴性患者血清miR-10b相对表达量比较差异无统计学意义(P>0.05)。结论血清miR-10b对乳腺浸润性导管癌有一定诊断价值,其升高可能与患者不良预后有关。Objective To investigate the expression and diagnostic value of serum miR-10b in patients with invasive ductal breast cancer, and to analyze its relationship with clinicopathological features. Methods The expression of serum miR-10b was detected by real-time fluorescence quantitative PCR in 29 patients with invasive ductal breast cancer(breast cancer group) and 48 healthy volunteers(control group). ROC curve was drawn to evaluate the value of serum miR-10b to the diagnosis of invasive ductal breast cancer, and to analyze the relationship between serum miR-10b and clinicopathological features. Results The relative expression of serum miR-10b was significantly higher in breast cancer group(2.140±1.769) than that in control group(1.408±1.328)(P<0.05). When the optimal cut-off value of serum miR-10b was 0.334, the AUC for diagnosing invasive ductal breast cancer was 0.646(95%CI: 0.523-0.769), the sensitivity was 89.70%, and the specificity was 41.70%. The relative expression of serum miR-10b was significantly higher in patients with lymph node metastasis before operation(3.449±1.855) than that in patients without lymph node metastasis(1.077±0.630)(P<0.05), and showed no significant difference in patients with different age, menstrual status, tumor diameter, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 positive or negative(P>0.05). Conclusion Serum miR-10b has a certain value in the diagnosis of invasive ductal breast cancer, and its high level might indicate a poor prognosis.

关 键 词：乳腺浸润性导管癌 MIR-10B 微小RNA 

分 类 号：R737.9[医药卫生—肿瘤]